Document is current
Any future updates will be listed below
-
Authors
Grech, Olivia https://orcid.org/0000-0001-5560-802X
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
Wakerley, Benjamin R. https://orcid.org/0000-0003-1016-5207
Alimajstorovic, Zerin https://orcid.org/0000-0001-5622-8301
Lavery, Gareth G. https://orcid.org/0000-0001-5794-748X
Sinclair, Alexandra J. https://orcid.org/0000-0003-2777-5132
-
Funding
Funding for this research was provided by:
Sir Jules Thorn Charitable Trust
Wellcome Trust
Brain Research UK
- License Information
-
More Information
Article History
Received: 18 May 2020
Revised: 14 July 2020
Accepted: 15 July 2020
First Online: 22 July 2020
Compliance with ethical standards
:
: OG—consultancy work for Invex therapeutics (2020). SPM—Invex therapeutics advisory board (2019); Heidelberg engineering speaker fees (2019). BW—consultancy work for Invex therapeutics (2020). ZA—no conflicts. GL—no conflicts. AJS—Novartis and Allergan Advisory board. Speaker fees Novartis. Invex therapeutics, company director with salary and stock options (2019, 2020).
